Is Amdocs (DOX) Still Undervalued After Its Share Price Slide?

Amdocs (DOX) has drawn investor attention after a period of weaker share performance, with the stock down over the month and the past 3 months, prompting closer scrutiny of its current valuation and fundamentals.

See our latest analysis for Amdocs.

At the latest share price of $51.91, Amdocs has seen its momentum fade, with the share price return down 7.96% over 30 days and year to date down 35.24%, contributing to a 39.54% decline in 1 year total shareholder return.

If this shift in sentiment has you reassessing your watchlist, it could be a good moment to broaden your search and check out 18 top founder-led companies

Amdocs now trades well below earlier levels, even as analysts publish a higher price target and its own model-based estimate points to a sizable discount. Is most of the potential upside still ahead or already used up?

Most Popular Narrative: 36.7% Undervalued

At a last close of $51.91 versus a narrative fair value of $82.03, Amdocs is framed as materially undervalued, with that gap explained by a detailed three step thesis.

Financially, the company is characterized by strong recurring revenue streams, highlighted by a high renewal rate for managed services, which account for approximately 65% of total revenue, and a substantial 12 month backlog of $4.28 billion. This stability allows the company to pursue a disciplined capital allocation strategy, featuring consistent dividend growth and significant share repurchases.

Read the complete narrative.

This narrative, according to HarishPK, focuses on how recurring revenue, backlog, and capital returns are incorporated into cash flow projections, profit margins, and the profit multiple used to reach that $82.03 figure.

Result: Fair Value of $82.03 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Amdocs still faces risks, including pressure on telecom customers that could affect its US$4.28b backlog and potential execution challenges as it shifts toward GenAI-led offerings.

Find out about the key risks to this Amdocs narrative.

Next Steps

If the mix of optimism and caution around Amdocs leaves you undecided, take a moment to review the data yourself and move quickly to shape your own view by starting with the 5 key rewards.

Looking for more investment ideas beyond Amdocs?

If Amdocs has sharpened your focus, do not stop here, use the Simply Wall Street Screener to surface fresh stocks that match your style and risk comfort.

• Target higher potential returns with disciplined risk by scanning carefully filtered opportunities through the screener containing 19 high quality undiscovered gems.
• Build a sturdier core portfolio by focusing on companies with healthier finances using the solid balance sheet and fundamentals stocks screener (47 results).
• Strengthen your downside protection by emphasizing stability and consistency via the 79 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com